{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:04Z","timestamp":1791327424923,"version":"4.3.1"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Associazione Franco Marcolin Onlus"},{"name":"Monica Fedeli and Edward Taylor"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Secondary antibody deficiencies (SAD) may require immunoglobulin replacement therapy (IgRT). While the intravenous route (IVIG) is broadly considered effective in SAD, the use of subcutaneous immunoglobulins (SCIG) is mainly adopted from the experience in primary antibody deficiencies (PAD), where SCIG have been shown to perform as effective as IVIG. However, evidence-based data on SCIG administration in SAD patients are still insufficient. Herein we retrospectively evaluated the efficacy and safety profile of SCIG treatment in 131 SAD patients as compared to a group of 102 PAD patients. We found SCIG being equally effective in reducing annual infectious rate both in SAD and PAD patients. However, SAD patients required lower SCIG dosage and lower IgG through level to achieve similar biological effect in terms of infection burden, at the steady state. SAD patients also showed better correlation between SCIG dose and serum IgG achieved value. Furthermore, within SAD, SCIG were found to work irrespective of the underlying disease. Especially in Non-Hodgkin Lymphoma patients, whose indication to IgRT is still not included in all guidelines and for whom evidence-based data are still lacking, SCIG were as effective as in Chronic Lymphocytic Leukemia or Multiple Myeloma patients, and SCIG discontinuation, without evidence of B cell recovery, led to IgG decline and relapsed infections. Finally, treatment tolerance in SAD patients was comparable to the PAD cohort. Globally, our data suggest that SCIG, as already appreciated in PAD, represent a valuable option in SAD patients, independent on the disease leading to antibody deficiency.<\/jats:p>","DOI":"10.1371\/journal.pone.0247717","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T13:36:50Z","timestamp":1614865010000},"page":"e0247717","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies"],"prefix":"10.1371","volume":"16","author":[{"given":"Francesco","family":"Cinetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":true,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Baril\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Gianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Lanciarotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rattazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1085-2333","authenticated-orcid":true,"given":"Riccardo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"pone.0247717.ref001","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","article-title":"Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy","volume":"100","author":"A Visentin","year":"2015","journal-title":"Haematologica"},{"key":"pone.0247717.ref002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"N Compagno","year":"2014","journal-title":"Front Immunol"},{"key":"pone.0247717.ref003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2016.11.020","article-title":"Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients","volume":"72","author":"A Visentin","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"pone.0247717.ref004","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/bjh.15849","article-title":"Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study","volume":"186","author":"G Baril\u00e0","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"pone.0247717.ref005","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.25011\/cim.v32i4.6622","article-title":"Immunological disturbances in Good\u2019s syndrome","volume":"32","author":"J Fijolek","year":"2009","journal-title":"Clin Invest Med"},{"issue":"10","key":"pone.0247717.ref006","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"DF Florescu","year":"2013","journal-title":"Am J Transplant."},{"issue":"4","key":"pone.0247717.ref007","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.iac.2008.06.001","article-title":"Intravenous gammaglobulin treatment in HIV-1 infection","volume":"28","author":"A Deener","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"pone.0247717.ref008","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"C Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"5","key":"pone.0247717.ref009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"SL Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0247717.ref010","first-page":"CD006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","author":"P Raanani","year":"2008","journal-title":"Cochrane database Syst Rev"},{"issue":"24","key":"pone.0247717.ref011","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1001\/jama.1990.03450240091046","article-title":"Intravenous immunoglobulin. Prevention and treatment of disease","volume":"264","author":"NIH consensus conference","year":"1990","journal-title":"JAMA"},{"key":"pone.0247717.ref012","author":"European Medicines Agency","year":"2018","journal-title":"Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg)"},{"key":"pone.0247717.ref013","author":"European Medicines Agency","year":"2015","journal-title":"Guideline on the Clinical Investigation of Human Normal Immunoglobulin for Subcutaneous and\/or Intramuscular Administration (SCIg\/IMIg)"},{"key":"pone.0247717.ref014","author":"ANB Authority","year":"2018","journal-title":"Acquired Hypogammaglobulinaemia Secondary to Haematological Malignancies, or Post-Haemopoietic Stem Cell Transplantation (HSCT)"},{"key":"pone.0247717.ref015","author":"ANB Authority","year":"2018","journal-title":"Secondary Hypogammaglobulinaemia Unrelated to Haematological Malignancy or Haemopoeitic Stem Cell Transplant (HSCT)"},{"key":"pone.0247717.ref016","author":"Alberta Ministry of Health, Shared Health Manitoba SM of H","year":"2018","journal-title":"Criteria for the Clinical Use of Immune Globulin"},{"issue":"3","key":"pone.0247717.ref017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"I Quinti","year":"2011","journal-title":"J Clin Immunol"},{"issue":"2","key":"pone.0247717.ref018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","article-title":"Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route","volume":"21","author":"A Gardulf","year":"2007","journal-title":"BioDrugs."},{"issue":"5","key":"pone.0247717.ref019","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/1744666X.2016.1155452","article-title":"A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis","volume":"12","author":"H Shabaninejad","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"pone.0247717.ref020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis","volume":"120","author":"LW Fu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"April","key":"pone.0247717.ref021","doi-asserted-by":"crossref","first-page":"108419","DOI":"10.1016\/j.clim.2020.108419","article-title":"Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study","volume":"215","author":"P Legendre","year":"2020","journal-title":"Clin Immunol"},{"issue":"1","key":"pone.0247717.ref022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/ejh.13078","article-title":"A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency","volume":"101","author":"O Benbrahim","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"pone.0247717.ref023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tmrv.2016.06.006","article-title":"Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy","volume":"31","author":"TM Windegger","year":"2017","journal-title":"Transfus Med Rev"},{"issue":"2","key":"pone.0247717.ref024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"M Berger","year":"2011","journal-title":"Clin Immunol"},{"issue":"1\u20132","key":"pone.0247717.ref025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s13554-014-0018-0","article-title":"Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency","volume":"4","author":"J Sidhu","year":"2014","journal-title":"Biol Ther."},{"key":"pone.0247717.ref026","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"VR Bonagura","year":"2008","journal-title":"The Journal of allergy and clinical immunology"},{"key":"pone.0247717.ref027","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0140-6736(95)90367-4","article-title":"Subcutaneous gammaglobulin for patients with secondary hypogammaglobulinaemia","volume":"345","author":"L Hammarstrom","year":"1995","journal-title":"Lancet (London, England)."},{"key":"pone.0247717.ref028","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clim.2016.04.001","article-title":"Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia","volume":"166\u2013167","author":"G Spadaro","year":"2016","journal-title":"Clinical immunology (Orlando, Fla.)"},{"key":"pone.0247717.ref029","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"A Vacca","year":"2018","journal-title":"Clin Immunol"},{"issue":"8","key":"pone.0247717.ref030","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1399-3046.2012.01783.x","article-title":"Subcutaneous IgG replacement after pediatric SCT","volume":"16","author":"M Sundin","year":"2012","journal-title":"Pediatr Transplant."},{"issue":"6","key":"pone.0247717.ref031","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"N Compagno","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"pone.0247717.ref032","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ejh.12900","article-title":"Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study","volume":"99","author":"M Reiser","year":"2017","journal-title":"Eur J Haematol"},{"issue":"4","key":"pone.0247717.ref033","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.intimp.2013.02.021","article-title":"Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients","volume":"15","author":"T Shankar","year":"2013","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"pone.0247717.ref034","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/2047-783X-15-6-238","article-title":"Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency","volume":"15","author":"F Hoffmann","year":"2010","journal-title":"Eur J Med Res"},{"issue":"6","key":"pone.0247717.ref035","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"M Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"pone.0247717.ref036","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/vox.12760","article-title":"Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency","volume":"114","author":"TM Windegger","year":"2019","journal-title":"Vox Sang"},{"issue":"1","key":"pone.0247717.ref037","first-page":"63","article-title":"Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy","volume":"11","author":"AP Koterba","year":"2015","journal-title":"Allergy, asthma, Clin Immunol Off J Can Soc Allergy Clin Immunol."},{"issue":"5","key":"pone.0247717.ref038","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"SK Kumar","year":"2008","journal-title":"Blood"},{"key":"pone.0247717.ref039","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1182\/blood-2009-04-214346","article-title":"Improving survival in patients with chronic lymphocytic leukemia (1980\u20132008): the Hospital Clinic of Barcelona experience","volume":"114","author":"P Abrisqueta","year":"2009","journal-title":"Blood."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T13:37:37Z","timestamp":1614865057000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247717"}},"subtitle":[],"editor":[{"given":"Maria Maddalena","family":"Sirufo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247717","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}